Entering text into the input field will update the search result below

XenoPort, Inc. (XNPT) Reports Active Ingredient In Horizant Guidelines For Treatment Of Restless Legs Syndrome

Jul. 23, 2013 3:41 PM ETXNPT
MissionIR profile picture
MissionIR's Blog
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered and developed drug candidates for the potential treatment of neurological disorders. The company is currently commercializing its first FDA-approved product, Horizant.

The company announced today the inclusion of gabapentin enacarbil, the active ingredient in Horizant® (gabapentin enacarbil) Extended-Release Tablets, as a first-line therapy in new treatment guidelines created by the Task Force of the International Restless Legs Syndrome Study Group (IRLSSG). This disease is a neurological condition that causes those afflicted to have an irresistible urge to move the legs. The urge is usually accompanied by unpleasant sensations of burning, creeping, tugging, or tingling inside the legs.

Horizant is the only non-dopamine agent and the only alpha-2-delta ligand currently approved by the FDA for the treatment of moderate-to-severe primary restless legs syndrome in adults. The newly-released guidelines indicate that alpha-2-delta ligands be considered for initial treatment in patients with severe sleep disturbance, insomnia or anxiety, RLS/WED-related pain, or a history of an impulse control disorder or anxiety. The guidelines also recommend a long-acting agent for patients with clinically significant daytime symptoms.

The release of these guidelines is an important breakthrough for Xenoport. There is growing recognition that dopamine agonists are not a sufficient answer for long-term treatment of patients with the disease. Most importantly, Horizant product is being recognized as an key treatment option for patients with RLS/WED.

For further information about XenoPort Inc., its Horizant product, and its whole portfolio of drug candidates, please visit www.xenoport.com

Please see disclaimer on the MissionIR website

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.